HOME >> BIOLOGY >> NEWS
ChemGenex reports successful personalized dosing of Quinamed at ASCO

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 4, 2007). ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the presentation of data from its Quinamed (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors. The key outcomes from this study were (i) demonstration that dose level could be optimised according to patient genotype, (ii) the drug was well tolerated, with predictable and manageable side effects, and (iii) there was evidence of anticancer activity in several solid tumor types.

Dr. John Kuhn of the University of Texas Health Science Center in San Antonio, TX, along with the investigators at Sarah Cannon Cancer Center, TN and University of Louisville, KY discussed the data in an oral presentation at the American Association of Clinical Oncology (ASCO) 43rd Annual Meeting in Chicago, Illinois.

The clinical activity of amonafide against a variety of cancers has long been recognized, but development has been hampered by the unpredictable side effect profile for patients said Dr Kuhn. We are excited by the new opportunities that personalized dosing of Quinamed offers for a range of solid tumor patients who have developed resistance to existing therapies.

Highlights of the presentation included:

  • Confirmation that genotyping of patients prior to treatment allows for optimized personalized dosing and improved drug tolerance.
  • Patients with rapid and intermediate acetylator genotypes (who more rapidly metabolize the drug to the acetylated derivative associated with side effects) achieved a maximum tolerated dose (MTD) of 320 mg/m2 of Quinamed weekly, whilst patients with slow acetylator genotypes achieved an MTD of 400 mg/m2 of Quinamed weekly (three weeks on treatment followed by one week off treatment, repeated). Using these dosing regimens, 64% of
    '"/>


Contact: Joan Kureczka
jkureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
4-Jun-2007


Page: 1 2

Related biology news :

1. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biosite reports on presentation of preliminary data from sepsis program
4. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
5. Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity
6. Dinosaurs climate shifted too, reports show
7. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
8. Portion distortion may contribute to expanding waistlines, study reports
9. Study reports findings on lung cancer death rates in never smokers
10. Breast implants not associated with cancer risk, study reports
11. Paper reports discovery of virus implicated in genetics of prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2019)... SAN DIEGO (PRWEB) , ... August 28, 2019 , ... ... The San Diego-based team building and cooking events company has seen record growth ... Teams, such as Amazon, ServiceNow, Vistage and Illumina, have all visited the company’s ...
(Date:8/27/2019)... ... , ... Shoreline Biome , a microbiome research company that develops tools ... its CEO and Karen Woodward as its VP of Business Development. , These ... products and expand the company’s sales worldwide. , Prior to joining Shoreline Biome, Bill ...
(Date:8/27/2019)... ... August 27, 2019 , ... Ambry Genetics ... improve genetic testing guidelines. In the largest cohort study of its kind, Ambry ... at-risk patients. , Clinicians use guidelines to inform decisions about which patients ...
Breaking Biology News(10 mins):
(Date:8/15/2019)... ... August 15, 2019 , ... PathSensors ... Lawrence is a member of the Institute of Food Technologists (IFT) Board of ... Advisory Board, Joint Institute for Food Safety and Applied Nutrition (JIFSAN) Advisory Council ...
(Date:8/8/2019)... ... August 08, 2019 , ... Inference Solutions , ... organizations, today announced that the company’s Studio Intelligent Virtual Agent (IVA) platform earned ... Inference will officially accept the award at Frost & Sullivan’s annual Excellence in ...
(Date:8/6/2019)... (PRWEB) , ... August 06, 2019 , ... ... tools for characterizing microbiome populations down to the strain level, has announced partnerships ... kits and other products to companies and research organizations in Australia, Benelux, Indonesia, ...
(Date:8/4/2019)... ... August 02, 2019 , ... Cirtec Medical Corporation, a strategic outsourcing partner for ... has begun construction on a 30,000 sq. ft. manufacturing facility in the Coyol ... , The facility, which is expected to be fully operational by the end of ...
Breaking Biology Technology:
Cached News: